Trospium Chloride XR in Obese Female Patients With Overactive Bladder
NCT ID: NCT00932022
Last Updated: 2013-01-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
127 participants
INTERVENTIONAL
2009-07-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
NCT01089751
Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder
NCT00196404
Investigation of Brain Mechanisms Involved in Urgency Urinary Incontinence
NCT04227184
Comparison of Caffeine Reduction and Anticholinergic Medications for Treatment of Overactive Bladder
NCT00780832
Study of V117957 in Overactive Bladder Syndrome
NCT06024642
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
trospium chloride XR 60 mg
Placebo capsule taken orally once daily for 2 weeks followed by trospium chloride extended release (XR) 60 mg capsule taken orally once daily for 12 weeks.
Trospium Chloride, Extended Release (XR)
Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
placebo
Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
placebo
Placebo capsule taken orally once daily for 14 weeks.
placebo
Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trospium Chloride, Extended Release (XR)
Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
placebo
Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Non-smoker (refrained from any tobacco usage, including smokeless tobacco, nicotine patches, etc., for 6 months prior to the screening visit).
* Obese
Exclusion Criteria
* Abdominal bypass surgery for obesity
* Moderate or severe memory impairment
* Uncontrolled narrow angle glaucoma
* Uncontrolled systemic disease
* Concurrent dementia drugs: Aricept (donepezil), Namenda (memantine), Cognex (tacrine), Exelon (rivastigmine), Razadyne (galantamine), or similar drugs for dementia
18 Years
75 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
La Mesa, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Sanctura XR obesity OAB Trial
Identifier Type: OTHER
Identifier Source: secondary_id
MA-SXR-09-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.